Ace Therapeutics is a trusted contract service provider specializing in developing tailored glucocorticoid-induced glaucoma models to support preclinical drug discovery and therapeutic validation. Our expertise empowers clients to study disease mechanisms, evaluate novel drugs, and optimize therapeutic strategies for glucocorticoid-associated ocular hypertension and optic nerve damage.
Glucocorticoid-Induced Glaucoma
Glucocorticoids (GCs) are widely used for their potent anti-inflammatory and immunosuppressive properties. However, prolonged administration—whether systemic, topical, or intraocular—can disrupt trabecular meshwork function, impair aqueous humor (AH) outflow, and elevate intraocular pressure (IOP). This IOP elevation is a primary risk factor for optic nerve degeneration and irreversible vision loss, mirroring key aspects of primary open-angle glaucoma (POAG). Understanding these mechanisms requires robust preclinical models that recapitulate human pathology, including IOP dynamics, retinal ganglion cell (RGC) apoptosis, and extracellular matrix remodeling in the trabecular meshwork. In this context, GC-induced ocular hypertension (OHT) models serve as a valuable tool to study the pathogenesis of glaucoma and to evaluate potential therapeutic interventions.
Fig. 1 Mechanism of glucocorticoid-induced ocular hypertension. (Pang I H and Clark A F., 2020)
Explore Our Glucocorticoid-Induced Glaucoma Models
Ace Therapeutics provides customizable in vivo models designed to mimic the progression of glucocorticoid-induced glaucoma, enabling comprehensive evaluation of therapeutics.
Available Glucocorticoid-Induced Glaucoma Models
We specialize in developing customizable models tailored to your research objectives. Whether you need specific GC doses, administration routes, or durations, our team can design a model that fits your requirements, ensuring relevant and reliable results.
- Dexamethasone-induced OHT models
We provide dexamethasone-induced OHT models that use systemic or topical administration to induce sustained IOP elevation in rodents and rabbits. These models are highly reproducible and clinically relevant, making them ideal for studying the pathogenesis of glucocorticoid-induced glaucoma.
We can also develop glucocorticoid-induced glaucoma models by periorbital or intravitreal injections of sustained-release formulations, ensuring sustained elevation of IOP over extended periods. These formulations can be customizable to meet your specific research needs, providing reliable and sustained IOP elevation for long-term studies.
Advantages of Our Glucocorticoid-Induced Glaucoma Models
- Reproducibility
- Clinical relevance
Glucocorticoid-Induced Glaucoma Model Evaluation Services
Our services extend beyond glucocorticoid-induced glaucoma model development to include:
- IOP measurement
- Analysis of histological and immunohistochemical characteristics of glaucoma
- Assessment of vision function
- Molecular and cellular analysis
Ophthalmic Technology Platform
Ace Therapeutics has powerful ophthalmic technology platforms that can comprehensively support your preclinical glaucoma research, including:
- Non-invasive IOP monitoring
- Optical coherence tomography (OCT)
- Electroretinography (ERG)
- Visual evoked potentials (VEP)
At Ace Therapeutics, our team of expert scientists specializes in developing and validating glucocorticoid-induced glaucoma models with meticulous attention to detail. We offer comprehensive support and tailored solutions to meet your specific research needs. Ready to partner with us? Contact us to discuss your project!
Reference
- Pang I H, Clark A F. Inducible rodent models of glaucoma. Prog Retin Eye Res, 2020, 75:100799.